CYP3A5 Antibody

1. CYP3A5, ABCB1 and two POR genotypes were assessed by real-time PCR. PMID: 28094348
2. (1S,2S)-2-hydroxylation also correlated to T-5 N-oxidation, a CYP3A5-specific activity. PMID: 29475834
3. Our data support that the CYP3A5*3 polymorphism may be associated with increased risk of prostate cancer, particularly in African populations. Large and well-designed studies are needed to validate this association. PMID: 29970707
4. CYP3A5 genetic differences were not associated with the development of interstitial fibrosis, any clinical events, or the long-term function and survival of kidney grafts PMID: 29550576
5. Concentrations of aripiprazole, sex, CYP3A5*3 and CYP2D6 were involved in the development of adverse drug reations to aripiprazole PMID: 29325225
6. CYP3A5 genetic polymorphism had a significant influence on tacrolimus pharmacological effects in Chinese liver transplantation patients PMID: 29454235
7. The results obtained by CLIA, ECLIA and ACMIA were not affected by CYP3A5 polymorphism. PMID: 28891077
8. CYP3A5 Polymorphism is associated with drug resistance in Breast Cancer. PMID: 29479969
9. In summary, we explored the effects of CYP3A5*3, UGT2B7*2, and UGT2B7*3 variants on steady-state carbamazepine (CBZ) concentrations in 62 epileptic patients. Our study found that the UGT2B7*2 variant, but not the CYP3A5*3 and UGT2B7*3 variants, can affect steady-state CBZ concentrations in these patients. PMID: 30045320
10. Our meta-analysis identified a positive correlation between CYP3A5 genotypes and tacrolimus pharmacokinetics in pediatric renal-transplant recipients PMID: 28540692
11. Stability of the dose-adjusted trough concentrations achieved using modified-release once-daily tacrolimus, which was clearly influenced by the CYP3A5 polymorphism, may prevent the development of rejection. PMID: 28271256
12. African-American kidney transplant recipients with the CYP3A5*1 variant require higher tacrolimus dosing. PMID: 28605053
13. the plasma trough concentration/dose (C/D) ratio of apixaban was used as a pharmacokinetic index and all data were stratified according to the presence of ABCB1 (ABCB1 1236C>T, 2677G>T/A, and 3435C>T), ABCG2 (ABCG2 421C>A), and CYP3A5 (CYP3A5*3) .These results indicate that ABCG2 421A/A and CYP3A5*3 genotypes and renal function are considered potential factors affecting trough concentrations of apixaban. PMID: 28678049
14. Patients with both CYP3A5*3/*3 and MDR1 G2677A who underwent renal transplantation had higher blood TAC concentrations than those without those genotypes. Japanese patients should be carefully monitored for consideration of lower TAC doses, because 24% of Japanese patients have double mutations. PMID: 28736028
15. Donor CYP3A5 genotype, recipient age and, to a lesser extent, donor gender appear to be associated with tacrolimus disposition on day 1 after transplant PMID: 28044353
16. The CYP3A5*3 gene polymorphism was closely associated with the mRNA expression of CYP3A5, CYP3A enzyme activity and DNR plasma drug concentration, and exhibited different drug adverse reactions. PMID: 28440407
17. The CYP3A5 genotype had no impact on the concentrations of cyclosporine A and tacrolimus at any investigated time point PMID: 29441922
18. We confirmed CYP3A5 metabolic activity with the CYP3A4 selective inhibitor CYP3CIDE. PMID: 28533324
19. Part of the differences in tacrolimus pharmacokinetics and transplantation outcomes may relate to differences between populations in the genetics of tacrolimus-metabolizing enzymes. The best-known example is the allelic frequency of the loss-of-function CYP3A5*3 allele. PMID: 27790923
20. conclude, therefore, that there is either no association between CYP3A5 expression and blood pressure or, if there is a relationship, the strength of the association is very small in Ghanaian population. PMID: 27334520
21. MDR1 and CYP3A5 genetic polymorphisms significantly influence plasma trough levels and therapeutic response of imatinib in patients with chronic myeloid leukemia. Patients with GG genotype for CYP3A5-A6986G (P=0.016) and TT genotype for MDR1-C3435T (P=0.013) polymorphisms had significantly higher trough levels of imatinib. PMID: 28330783
22. The CYP3A5 gene may be associated with the risk of hypertension in the Chinese Han population, and this effect may be exacerbated by drinking. PMID: 28448186
23. The study demonstrated no correlation between CYP3A5 genotype and the development of vincristine neurotoxicity in childhood malignancies. PMID: 28697165
24. The A/G genotypes, G/G genotypes, and G allele of CYP3A5*3 in the LEDVT group were observed with increased frequency compared with the control group. The genotype distributions of the CYP2C9*3, CYP2D6*10, and CYP3A5*3 genetic polymorphisms were associated with the warfarin maintenance dose. PMID: 28872889
25. Steroid resistance during acute renal allograft rejection is associated with donor genotype and intragraft expression levels of CYP3A5. PMID: 27926596
26. A significant association of CYP3A5 genotypes was found with tacrolimus daily dose in kidney transplant recipients. PMID: 27977332
27. The authors found a correlation between genetic SNP variations in CYP3A5 enzyme and tacrolimus blood levels in this Jordanian kidney transplant recipients. PMID: 27225724
28. In patients with ulcerative colitis treated with tacrolimus, the incidence of nephrotoxicity was significantly higher in CYP3A5 expressers compared to non-expressers. PMID: 27717793
29. The present study evaluated the ability of a Saccharomyces cerevisiae expression system to predict the pharmacokinetic (PK) activity of a calcium channel blocker in patients with distinct cytochrome P450 3A5 (CYP3A5) polymorphisms. PMID: 28259948
30. In the CYP3A5*3/*3 group, the concentration of tacrolimus was significantly higher in men than in women in Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients. PMID: 28324194
31. There are no significant differences in serum creatinine, haematocrit and albumin values between CYP3A5 expressers and non-expressers. PMID: 27885697
32. population pharmacokinetic analysis identified that the combined genotype of CYP3A5-POR was the only covariant for the apparent clearance of tacrolimus PMID: 26227094
33. The GG and TT genotypes in CYP3A5*3 and ABCB1 C3435T, respectively, were linked with higher TPC. PMID: 27426203
34. CYP3A5 single nucleotide polymorphisms are associated with Clopidogrel Resistance in Acute Ischemic Stroke. PMID: 26961113
35. There was no significant correlation between CYP3A5 rs776746 polymorphism and major adverse events of clopidogrel therapy. [Meta-Analysis] PMID: 27649539
36. pharmacokinetics of once-daily tacrolimus formulation in relation to polymorphisms of the donor cytochrome P450 family 3 sub-family A polypeptide 5 (CYP3A5) gene and recipient adenosine triphosphate-binding cassette sub-family B member 1 (ABCB1) gene in 80 consecutive living-donor liver transplant recipients PMID: 27503662
37. CYP3A5 (6986A > G) genotype, rather than MDR-1 (2677G > A/T) variant, has an impact on tacrolimus pharmacokinetics PMID: 26856709
38. study to determine the impact of CYP3A5 genetic polymorphisms on paclitaxel/carboplatin-induced myelosuppression and neurotoxicity in patients with epithelial ovarian cancer; found that CYP3A5*3*3 was associated with a lower risk of paclitaxel/carboplatin-induced myelosuppression compared with other CYP3A5 genotypes PMID: 26179145
39. Liver transplant patients with CYP3A5 polymorphisms required significantly higher doses of tacrolimus to achieve target blood concentrations. PMID: 27320564
40. CYP3A5 genetic polymorphisms in Uyghur population. PMID: 26739429
41. The results suggest that early post-transplantation bioavailability differences in time to reach tacrolimus therapeutic levels are due to CYP3A5 genotype. This also appears to affect graft rejection and survival. PMID: 27110018
42. CYP3A5 and MDR1 polymorphisms may be the main explanation for the differences observed in RUP pharmacokinetics. PMID: 25427746
43. that there was association between CYP3A5 FNx01 3 polymorphism and the altered risk of acute lymphoblastic leukemia in children, especially in Caucasian populations PMID: 25673168
44. Cyclosporin A-based maintenance therapy is safe for Chinese de novo kidney transplant recipients who are CYP3A5 expressers. PMID: 26177348
45. CYP3A5 and ABCB1-1236 genotyping, in addition to recipient age, are necessary for establishing a more accurate TAC dosage regimen in paediatric liver recipients. PMID: 26176181
46. Patients with CYP3A5*1*1 genotypes require higher doses of tacrolimus to achieve the target concentration and may be at risk of acute rejection soon after transplant because of inadequate immunosuppression. PMID: 26177012
47. We herein discuss all published data on the contribution of CYP3A5 and its polymorphisms to the metabolism of antipsychotics and antidepressants that are known to be metabolized by CYP3A enzymes, as well as of carbamazepine, an antiepileptic drug used as mood stabilizer PMID: 26651976
48. Although CYP3A5 polymorphism significantly influenced the tacrolimus dose required to achieve the target concentration, the impact of CYP3A5 polymorphism on biopsy-proven acute rejection was not observed in this study PMID: 26635230
49. The requirement for daily maintenance dose was higher in those with CYP3A5*1/*1 variants in both tacrolimus formulations in the Malaysian Renal Transplant patients. Furthermore, those with CYP3A5*3/*3 demonstrated significantly higher dose-adjusted within-patient variability trough levels with Advograf. PMID: 26915847
50. Loss-of-function variants in CYP3A5 is associated with tacrolimus trough concentrations in African American kidney allograft recipients. PMID: 26485092

顯示更多

收起更多

HGNC: 2638

OMIM: 605325

KEGG: hsa:1577

STRING: 9606.ENSP00000222982

UniGene: Hs.571258